Inovio Pharmaceuticals, Inc. INO
1.62 USD -0.04 (-2.41%)
At closeNov 4, 2026, 5:38 PM EST
1.61 -0.01 -0.62%
After hours · Nov 4, 5:38 PM ET
1.55 Day range 1.85
0.56 52-week range 2.72
- YTD
- -6.90%
- 1 year
- -33.33%
Analyst view
Consensus: buy
Buy
Price target (mean) 10.67 +558.4% upside
Now 1.62
- Target (low)
- 5.00
- Target (mean)
- 10.67
- Target (high)
- 18.00
Ratings (0m) 6 3 buy · 3 hold · 0 sell
- Strong buy1
- Buy2
- Hold3
- Sell0
- Strong sell0
Recommendation trend
- This month 6
- 1 month ago 6
- 2 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.928 | -1.04 – -0.77 | -5.67 | +83.6% | 30.00K | -70.8% | 5 |
| Next quarter | -1.08 | -1.08 – -1.08 | -1.31 | +17.6% | 100.00K | 0.0% | 1 |
| Current year | -4.39 | -4.71 – -4.09 | -6.09 | +27.9% | 130.60K | -84.3% | 5 |
| Next year | -3.74 | -4.78 – -2.16 | -4.39 | +14.9% | 2.60M | +1889.7% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 18, 2024 | HC Wainwright & Co. | Maintained | Neutral | Neutral |
| Nov 18, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Nov 15, 2024 | RBC Capital | Maintained | Sector Perform | Sector Perform |
| Aug 12, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Aug 9, 2024 | RBC Capital | Maintained | Sector Perform | Sector Perform |
| Jul 15, 2024 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| May 14, 2024 | Stephens & Co. | Initiated | — | Overweight |
| Mar 8, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Mar 7, 2024 | RBC Capital | Reiterated | Sector Perform | Sector Perform |
| Jan 25, 2024 | Oppenheimer | Upgrade | Perform | Outperform |